This asset is one of five IDO1 inhibitors in clinical development worldwide and EOS200271 is the only IDO1 inhibitor with excellent
brain penetration confirmed in patients.
200271 is distinguished through its high level of
brain penetration confirmed in clinical trials.
Not exact matches
While EOS200271 was originally licensed from iTeos to Pfizer in December 2014, the candidate was returned to iTeos at the end of 2017, after demonstrating interim data from 17 patients which
confirmed the safety and
brain penetration of EOS200271 at doses ranging up to 500 mg BID.
Interim data from 17 patients
confirmed the safety and
brain penetration of EOS200271 at doses ranging up to 500 mg BID, the maximum dose tested by Pfizer in the study.